<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01699347</url>
  </required_header>
  <id_info>
    <org_study_id>CMC-11-0059-CTIL</org_study_id>
    <nct_id>NCT01699347</nct_id>
  </id_info>
  <brief_title>Cohort Prospective Study of Children With Head and Neck Cystic Malformation Who Are Treated With Intracystic OK432</brief_title>
  <acronym>OK432</acronym>
  <official_title>Cohort Prospective Study of Children With Head and Neck Cystic Malformation Who Are Treated With Intracystic OK432</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carmel Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Carmel Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cohort study evaluate the efficacy treatment with OK-432 in cystic malformation of the head&#xD;
      and neck region.&#xD;
&#xD;
      The malformations are macrocystic and the preevaluation will include CT/MRI, US and blood&#xD;
      tests.&#xD;
&#xD;
      The injection will be in the OR under US guided, maximal dose will be 0.2mg. The follow-up&#xD;
      will be of short term - till 30 days post injection and long term - follow-up wil be till 2&#xD;
      years.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A cohort study, before the injection all the patients in the study will go through:&#xD;
&#xD;
        1. CT/MRI&#xD;
&#xD;
        2. US to estimate the cyst size&#xD;
&#xD;
        3. CBC, PT, PTT, INR, ASLO&#xD;
&#xD;
        4. ECG If the patient is qualified to the study the parent will sign on the inform consent,&#xD;
           than the child will be photographed AP and lateral.&#xD;
&#xD;
      The injection will be held in the OR under US guidance with 18q20 gauge needle, first all the&#xD;
      cyst contents will be sucked than the OK432 will be injected in.&#xD;
&#xD;
      After the injection the child will stay for one night if it was general anesthesia and 4&#xD;
      hours in the case of local anesthesia.&#xD;
&#xD;
      Short term follow - 3-5 days with the phone, up: till 30 days from the injection with US,&#xD;
      stills photo.&#xD;
&#xD;
      Long term follow-up: 6 months, 1 year, 2 years&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>evaluation of the efficacy in treating cystic malformation with OK432 by measuring time that elapsed without recurrence</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>TREATMENT SAFETY BY no. of participants with adverse events</measure>
    <time_frame>4 YEARS</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">5</enrollment>
  <condition>CYSTIC MALFORMATION</condition>
  <arm_group>
    <arm_group_label>OK432</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intracystic injection of OK432 under US guiding</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intracystic injection of OK432 under US guiding</intervention_name>
    <description>Intracystic injection of OK432 under US guiding</description>
    <arm_group_label>OK432</arm_group_label>
    <other_name>OK432 (Picibanil)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  LYMPHATIC MALFORMATION MACROCYSTIC OR MIXED WITH MORE THEN 50% MACROCYSTIC.&#xD;
&#xD;
          -  ONLY IN THE HEAD AND NECK AREA&#xD;
&#xD;
          -  TIME FROM OPERATION AT LEAST 6 MONTHS&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  penicillin allergy&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  familial history of RF&#xD;
&#xD;
          -  Post streptococcal glomerulonephritis&#xD;
&#xD;
          -  Background illness-heart, kidney, lungs&#xD;
&#xD;
          -  fever &gt; 38.5c in the op day&#xD;
&#xD;
          -  URT Infection&#xD;
&#xD;
          -  Family history of PANDAS&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raanan Cohen-Kerem, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Carmel Medical Center, Haifa, Israel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Otolaryngology, Carmel Medical Center</name>
      <address>
        <city>Haifa</city>
        <zip>34362</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raanan Cohen-Kerem, MD</last_name>
      <phone>+97248250279</phone>
      <email>raanan@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Raanan Cohen-Kerem, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <study_first_submitted>August 19, 2012</study_first_submitted>
  <study_first_submitted_qc>September 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2012</study_first_posted>
  <last_update_submitted>November 28, 2013</last_update_submitted>
  <last_update_submitted_qc>November 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>OK432, CYSTIC MALFORMATION</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Congenital Abnormalities</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Picibanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

